Bullish Moving Averages
15
Bearish Moving Averages
1
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
1200.10Today’s High
1225.8052W low
707.2052W High
1285.00Open Price
1220.00Prev. Close
1247.7000Volume
113709.00Value
136899950.55Fundamentals
Market Cap
23665.20
Price to Earnings
37.60
Price to Book Value
4.90
Dividend Yield
0.90
PE to Growth
2.00
Op Revenue TTM
6304.21
Net Profit TTM
629.92
Cash From Operating Activity
803.20
Return on Equity %
12.78
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
12 Sep, 2024
41.3
Week
22.9
Month
28.4
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
1235.32
PIVOT
First Resistance
1259.53
Second Resistance
1302.22
Third Resistance
1326.43
First Support
1192.63
Second Support
1168.42
Third Support
1125.73
Relative Strength Index
61.96
Money Flow Index
82.51
MACD
29.39
MACD Signal
12.7
Average True Range
55.9
Average Directional Index
24.71
Rate of Change (21)
13.92
Rate of Change (125)
24.39
Day Commodity Channel Index
176.1
Day Williams %R
-24.2
BETA
1 Month
0.87
3 Month
0.19
1 Year
0.69
3 Year
0.22
PRICE CHANGE ANALYSIS
↑ 4.95%
1 Week
Low
High
1101.25
1278
↑ 8.39%
1 Month
Low
High
1025.1
1278
↑ 35.09%
3 Months
Low
High
837.8
1284.95
↑ 22.81%
6 Months
Low
High
823.4
1284.95
↑ 60.3%
1 Year
Low
High
707.15
1284.95
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 1478.70 | 1481.77 | 1591.69 | 1487.80 | 1344.12 | 1309.08 | 1310.79 | 1354.89 | 1160.95 | 1315.91 | 1234.25 | 1191.48 | 1271.43 | |
| Operating Expenses Qtr | 1184.13 | 1186.36 | 1251.25 | 1271.38 | 1166.54 | 1137.94 | 1085.98 | 1109.13 | 1033.70 | 1013.01 | 950.08 | 952.82 | 992.72 | |
| Operating Profit Qtr | 291.42 | 288.19 | 337.14 | 207.46 | 165.73 | 169.18 | 224.23 | 245.29 | 126.63 | 291.30 | 282.75 | 236.95 | 276.97 | |
| EBIDT Qtr Cr | 294.57 | 295.41 | 340.44 | 216.41 | 177.57 | 171.14 | 224.81 | 245.76 | 127.25 | 302.90 | 284.16 | 238.66 | 278.71 | |
| Depreciation Qtr | 68.68 | 69.12 | 69.08 | 67.18 | 65.75 | 73.54 | 65.85 | 66.80 | 46.09 | 45.95 | 45.34 | 44.53 | 43.49 | |
| Net Profit Qtr | 176.19 | 201.87 | 233.24 | 133.84 | 97.53 | 130.54 | 119.13 | 146.44 | 72.46 | 251.37 | 193.58 | 156.35 | 192.69 | |
| Basic EPS Qtr | 8.96 | 10.27 | 11.87 | 6.81 | 4.96 | 6.64 | 6.06 | 7.45 | 3.69 | 12.79 | 9.85 | 7.95 | 9.80 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 5905.38 | 5152.54 | 5086.55 | 5061.17 | 4267.30 | |
| Operating Expenses Annual Cr | 4875.54 | 4484.65 | 4126.61 | 3479.21 | 2929.65 | |
| Operating Profit Annual | 998.52 | 664.35 | 908.80 | 1572.23 | 1202.90 | |
| Operating Profit Margin Annual % | 16.91 | 12.89 | 17.87 | 31.06 | 28.19 | |
| Total Expenses Annual Cr | 5201.15 | 4806.60 | 4428.55 | 3644.58 | 3090.51 | |
| EBIDT Annual Cr | 1029.84 | 667.89 | 959.94 | 1581.96 | 1337.65 | |
| EBIDT Annual margin % | 17.44 | 12.96 | 18.87 | 31.26 | 31.35 | |
| Depreciation | 271.14 | 272.95 | 284.92 | 152.60 | 135.67 | |
| PAT Before ExtraOrdinary Items Annual Cr | 666.48 | 346.73 | 543.55 | 1175.39 | 969.40 | |
| Net Profit Annual | 666.48 | 346.73 | 543.55 | 1175.39 | 969.40 | |
| Basic EPS Annual | 33.91 | 17.64 | 27.65 | 60.67 | 51.42 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 4908.91 | 4414.29 | 5290.34 | 5254.24 | 3346.02 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 162.42 | 164.83 | 204.25 | 398.47 | 1079.26 | |
| Total Current Liabilities Annual Cr | 1327.21 | 1551.30 | 1579.45 | 1123.47 | 1453.49 | |
| Total Capital Plus Liabilities Annual Cr | 6398.54 | 6130.42 | 7074.04 | 6776.18 | 5878.77 | |
| Fixed Assets Annual | 3060.02 | 2978.73 | 4075.33 | 3388.81 | 2846.44 | |
| Total Non Current Assets Annual | 3409.99 | 3350.20 | 4329.58 | 4402.23 | 3727.40 | |
| Total Current Assets Annual | 2988.55 | 2780.22 | 2744.46 | 2373.95 | 2151.37 | |
| Total Assets Annual | 6398.54 | 6130.42 | 7074.04 | 6776.18 | 5878.77 | |
| Contingent Liabilities plus Commitments Annual Cr | 193.55 | 326.18 | 228.15 | 327.06 | 455.59 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 772.77 | 730.25 | 545.26 | 1485.30 | 539.75 | |
| Cash from Investing Activity Annual | -329.02 | -460.98 | -368.72 | -925.55 | -822.31 | |
| Cash from Financing Annual Activity | -445.29 | -261.16 | -216.64 | -533.60 | 166.13 | |
| Net Cash Flow Annual | -1.54 | 8.11 | -40.10 | 26.15 | -116.43 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 249.75 | 224.59 | 269.16 | 267.32 | 177.51 | |
| ROE Annual % | 13.57 | 7.85 | 10.27 | 22.37 | 28.97 | |
| ROCE Annual % | 14.96 | 8.62 | 12.28 | 25.28 | 27.16 | |
| Total Debt to Total Equity Annual | 0.09 | 0.14 | 0.12 | 0.04 | 0.50 | |
| EBDIT Annual Margin % | 17.53 | 12.97 | 19.06 | 31.31 | 32.36 |
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 1563.83 | 1520.58 | 1633.46 | 1605.09 | 1497.81 | 1407.34 | 1509.46 | 1475.34 | 1263.22 | 1426.01 | 1273.04 | 1294.52 | 1327.91 | |
| Operating Expenses Qtr | 1324.90 | 1256.92 | 1364.21 | 1386.69 | 1287.46 | 1194.23 | 1260.27 | 1242.27 | 1247.49 | 1255.63 | 1016.05 | 1035.09 | 1090.10 | |
| Operating Profit Qtr | 236.83 | 260.06 | 266.36 | 208.25 | 198.69 | 212.22 | 248.75 | 232.74 | 14.65 | 160.11 | 255.65 | 257.23 | 235.93 | |
| EBIDT Qtr Cr | 238.93 | 263.66 | 269.25 | 218.40 | 210.35 | 213.11 | 249.19 | 233.07 | 15.73 | 170.38 | 257.00 | 259.43 | 237.81 | |
| Depreciation Qtr | 69.04 | 69.48 | 69.45 | 67.56 | 66.18 | 74.12 | 66.51 | 67.70 | 67.10 | 123.08 | 55.94 | 54.60 | 53.15 | |
| Net Profit Qtr | 134.71 | 178.21 | 180.45 | 136.56 | 120.60 | 152.60 | 121.92 | 133.35 | -65.88 | 35.46 | 176.42 | 169.29 | 158.27 | |
| Basic EPS Qtr | 6.85 | 9.07 | 9.18 | 6.95 | 6.14 | 7.76 | 6.20 | 6.78 | -3.35 | 1.80 | 8.98 | 8.61 | 8.37 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 6256.93 | 5655.36 | 5356.25 | 5403.15 | 4610.69 | |
| Operating Expenses Annual Cr | 5295.27 | 4944.24 | 4431.63 | 3835.58 | 3382.73 | |
| Operating Profit Annual | 933.35 | 708.38 | 874.16 | 1557.55 | 1223.02 | |
| Operating Profit Margin Annual % | 14.92 | 12.53 | 16.32 | 28.83 | 26.53 | |
| Total Expenses Annual Cr | 5624.13 | 5269.84 | 4736.14 | 4035.07 | 3567.21 | |
| EBIDT Annual Cr | 961.66 | 711.12 | 924.62 | 1567.57 | 1227.96 | |
| EBIDT Annual margin % | 15.37 | 12.57 | 17.26 | 29.01 | 26.63 | |
| Depreciation | 272.67 | 275.43 | 286.78 | 183.47 | 157.32 | |
| PAT Before ExtraOrdinary Items Annual Cr | 616.80 | 372.91 | 515.65 | 1114.76 | 800.65 | |
| Net Profit Annual | 615.82 | 341.99 | 520.94 | 1178.11 | 828.82 | |
| Basic EPS Annual | 31.33 | 17.40 | 26.50 | 60.81 | 43.97 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 4818.20 | 4370.47 | 5237.54 | 5127.61 | 3219.41 | |
| Minority Interest Liability Annual Cr | 0.00 | 0.00 | 0.00 | -60.64 | -28.96 | |
| Total Non Current Liabilities Annual Cr | 172.39 | 175.43 | 167.96 | 361.16 | 1046.99 | |
| Total Current Liabilities Annual Cr | 1454.99 | 1636.93 | 1716.53 | 1280.85 | 1751.60 | |
| Total Capital Plus Liabilities Annual Cr | 6445.58 | 6182.83 | 7122.03 | 6708.98 | 5989.04 | |
| Fixed Assets Annual | 3071.07 | 2999.73 | 4102.08 | 3970.96 | 3398.02 | |
| Total Non Current Assets Annual | 3367.02 | 3272.81 | 4261.24 | 4131.08 | 3526.30 | |
| Total Current Assets Annual | 3078.56 | 2910.02 | 2860.79 | 2577.90 | 2462.74 | |
| Total Assets Annual | 6445.58 | 6182.83 | 7122.03 | 6708.98 | 5989.04 | |
| Contingent Liabilities plus Commitments Annual Cr | 183.13 | 317.96 | 228.15 | 349.23 | 386.98 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 803.20 | 723.95 | 552.36 | 1463.38 | 449.13 | |
| Cash from Investing Activity Annual | -320.61 | -447.59 | -371.97 | -838.81 | -731.63 | |
| Cash from Financing Annual Activity | -437.86 | -261.96 | -217.36 | -597.42 | 154.86 | |
| Net Cash Flow Annual | 44.73 | 14.40 | -36.97 | 27.15 | -127.64 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 245.14 | 222.36 | 266.47 | 257.80 | 169.25 | |
| ROE Annual % | 12.78 | 7.82 | 9.94 | 22.97 | 25.74 | |
| ROCE Annual % | 13.80 | 9.58 | 11.79 | 25.49 | 25.26 | |
| Total Debt to Total Equity Annual | 0.09 | 0.15 | 0.12 | 0.04 | 0.54 | |
| EBDIT Annual Margin % | 15.43 | 12.58 | 17.42 | 29.06 | 26.66 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| Kotak Small Cap Fund | 1.76 | 88385152 | - | - |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| Chirayu Ramanbhai Amin | 2.13 | 88385114 | 0 | 0 |
| Malika Chirayu Amin | 1.53 | 88385115 | 0 | 0 |
| Pranav Chirayu Amin | 0.51 | 88385116 | 0 | 0 |
| Shaunak Chirayu Amin | 0.51 | 88385117 | 0 | 0 |
| Nirayu Limited | 35.63 | 88385125 | 0 | 0 |
| Alembic Limited | 28.54 | 88385126 | 0 | 0 |
| Udit Chirayu Amin | 0.51 | 88385147 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| DSP Midcap Fund | 4.2 | 88385151 |
| Kotak Small Cap Fund | 1.76 | 88385152 |
| Life Insurance Corporation Of India | 4.33 | 88385154 |
| Name | Holding Percent | Holding Id |
|---|
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Jul 15, 2024 | 11 | FINAL | Jul 15, 2024 | Equity Share |
| Jul 28, 2023 | 8 | FINAL | Jul 28, 2023 | Equity Share |
| Aug 17, 2022 | 10 | INTERIM | Aug 18, 2022 | Equity Share |
| Jul 19, 2021 | 14 | FINAL | - | Equity Share |
| Mar 16, 2020 | 7 | INTERIM | Mar 17, 2020 | Equity Share |
| Mar 16, 2020 | 3 | SPECIAL | Mar 17, 2020 | Equity Share |
| Jul 18, 2019 | 5.5 | FINAL | - | Equity Share |
| Jul 18, 2018 | 4 | FINAL | - | Equity Share |
| Jul 11, 2017 | 4 | FINAL | - | Equity Share |
| Jul 20, 2016 | 4 | FINAL | - | Equity Share |
| Jul 22, 2015 | 3.5 | FINAL | - | Equity Share |
| Jul 17, 2014 | 3 | FINAL | - | Equity Share |
| Jul 29, 2013 | 2.5 | FINAL | - | Equity Share |
| Jul 31, 2012 | 1.4 | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| Aug 08, 2024 | Quarterly Results | - |
| May 09, 2024 | Audited Results & Final Dividend | - |
| Feb 05, 2024 | Quarterly Results | - |
| Nov 07, 2023 | Quarterly Results | - |
| Aug 04, 2023 | Quarterly Results | - |
| May 05, 2023 | Audited Results & Final Dividend | - |
| Feb 01, 2023 | Quarterly Results | - |
| Nov 11, 2022 | Quarterly Results | - |
| Aug 04, 2022 | Quarterly Results & Others | To change dividend type from Final Dividend to Interim Dividend |
| May 02, 2022 | Audited Results & Dividend | - |
| Feb 10, 2022 | Quarterly Results | - |
| Nov 10, 2021 | Quarterly Results | - |
| Jul 26, 2021 | Quarterly Results | - |
| May 04, 2021 | Audited Results & Dividend | - |
| Jan 19, 2021 | Quarterly Results | - |
| Oct 22, 2020 | Quarterly Results | - |
| Aug 06, 2020 | To consider raising of funds | - |
| Jul 27, 2020 | Others | Inter alia to consider fund raising by way of a qualified institutions placement. |
| Jul 22, 2020 | Quarterly Results | - |
| May 22, 2020 | Audited Results | - |
| Apr 23, 2020 | Quarterly Results | - |
| Mar 06, 2020 | Interim Dividend | - |
| Jan 22, 2020 | Quarterly Results | - |
| Oct 24, 2019 | Quarterly Results | - |
| Jul 29, 2019 | Quarterly Results | - |
| Jun 12, 2019 | Others | inter alia, to consider and approve the proposal for issue of NonConvertible Debentures on Private Placement Basis. |
| May 08, 2019 | Audited Results & Dividend | - |
| Jan 22, 2019 | Quarterly Results | - |
| Dec 14, 2018 | Others | To consider and approve the issue and allotment of Unsecured Redeemable Non-Convertible Debentures (NCDs) of upto Rs. 350 Crores on Private Placement Basis. |
| Dec 06, 2018 | Others | To consider and approve a fresh proposal for issue of Non-Convertible Debentures on Private Placement Basis, superceding the earlier resolution. |
| Oct 22, 2018 | Quarterly Results | - |
| Sep 10, 2018 | Others | To consider the proposal for issue of Non-Convertible Debentures on Private Placement Basis. |
| Jul 27, 2018 | Quarterly Results | - |
| May 16, 2018 | Audited Results & Dividend | - |
| Jan 31, 2018 | Quarterly Results | - |
| Nov 07, 2017 | Quarterly Results | - |
| Jul 20, 2017 | Quarterly Results | - |
| May 03, 2017 | Audited Results & Dividend | - |
| Jan 25, 2017 | Quarterly Results | - |
| Oct 25, 2016 | Quarterly Results | - |
| Jul 29, 2016 | Quarterly Results | - |
| Apr 27, 2016 | Audited Results & Dividend | - |
| Jan 21, 2016 | Quarterly Results | - |
| Oct 27, 2015 | Quarterly Results | - |
| Jul 31, 2015 | Quarterly Results | - |
| Apr 27, 2015 | Audited Results & Dividend | Appointed Mr. Pranav Amin as Joint Managing Director w.e.f. April 27, 2015. |
| Feb 04, 2015 | Quarterly Results | - |
| Oct 20, 2014 | Quarterly Results | - |
| Jul 28, 2014 | Quarterly Results | - |
| Apr 28, 2014 | Audited Results & Dividend | - |
| Jan 22, 2014 | Quarterly Results | - |
| Oct 25, 2013 | Quarterly Results | (Revised) |
| Aug 07, 2013 | Quarterly Results | - |
| May 02, 2013 | Audited Results & Dividend | - |
| Jan 21, 2013 | Quarterly Results | - |
| Oct 19, 2012 | Quarterly Results | - |
| Aug 09, 2012 | Quarterly Results | - |
| Apr 25, 2012 | Audited Results & Dividend | - |
| Feb 08, 2012 | Quarterly Results | - |
| Oct 19, 2011 | Quarterly Results | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|
12 Sep 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find attached herewith the Intimation received from our RTA.
05 Sep 2024
Alembic Pharma Gets USFDA Approval For Drug That Treats Worm Infections
Albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.
05 Sep 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alembic Pharmaceuticals receives USFDA Final Approval for Albendazole Tablets USP, 200 mg.
02 Sep 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find attached herewith the intimation received from our RTA.
30 Aug 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
The Company has received an Assessment Order from Office of the Deputy Commissioner of State Tax, Sector - 09, Lucknow, Uttar Pradesh.
29 Aug 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
The Company has received an assessment order from the office of Deputy Commissioner of Commercial Taxes, DGSTO-2, Bengaluru, Karnataka.
27 Aug 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find attached herewith the Intimation for the Analyst / Fund Manager / Investor Meet
27 Aug 2024
Alembic Pharma shares rise after USFDA approval; check details here
Shares of Alembic Pharmaceuticals soared up to 4.13 per cent at Rs 1,135 per share on the BSE
24 Aug 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alembic Pharmaceuticals receives USFDA Final Approval for Betamethasone Valerate Foam, 0.12%.
22 Aug 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Change in Management
Resignation of SMP
